-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Annals of the Rheumatic Diseases, a top journal in the field of rheumatism, published a research article, researchers aiming to evaluate rheumatoid arthritis (RA) and psoriatic arthritis treated with tumor necrosis factor inhibitor (TNFi) (PsA) the incidence of severe infection (SI) in patients, and compare the risk of severe infection (SI) in RA patients and PsA patients
.
The researchers enrolled RA and PsA patients who had started TNFi treatment from the Norwegian-Disease Modification Antirheumatic Drug Registry, and calculated the rough incidence (IR) and IR ratios of SI
.
The researchers used an adjusted Cox regression model to compare the risk of SI in patients with RA and PsA
A total of 3169 TNFi treatment courses were identified in 2359 patients (RA/PsA: 1778/1391)
.
The age of RA patients has increased significantly, and a wider range of combination medications are used at the same time
The rough IR of SI for RA patients was 4.
17 (95% CI 3.
52 to 4.
95), and for PsA patients it was 2.
16 (95% CI 1.
66 to 2.
81)
.
In the complete set analysis, compared with RA patients, PsA patients had a lower risk of SI (HR 0.
It can be seen that compared with RA patients, PsA patients have a significantly lower risk of SI during TNFi treatment
.
.
Original source:
Original source:Ingrid Egeland Christensen,et al.
Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study in this message
